A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignancies

ConclusionsThe MTD of oratecan was encequidar methanesulfonate 15 mg plus irinotecan 280 mg/m2. Exposure for irinotecan and SN-38 increased with increased dose. Potential antitumor activity was observed at the 280 and 320 mg/m2 dose levels. The safety profile of oratecan was comparable to that of intravenous irinotecan.

http://link.springer.com/10.1007/s00280-022-04453-z

Source: Cancer Chemotherapy and Pharmacology - July 29, 2022 Category: Cancer & Oncology Source Type: research